Zodak (cetirizine digidrochloride) oral drops 10 mg/ml. 20 ml. vial №1

Description

Zodak (cetirizine digidrochloride) oral drops 10 mg/ml. 20 ml. vial №1

Composition

active substance: cetirizine dihydrochloride;

1 ml of solution contains cetirizine dihydrochloride 10 mg;

Excipients: methylparaben (E 218); propylparaben (E 216); glycerin (85%); propylene glycol; saccharin sodium; sodium acetate trihydrate; glacial acetic acid; purified water.

Dosage form

Oral drops.

Main physical and chemical properties: clear, colorless or slightly yellowish solution.

Pharmacotherapeutic group

Antihistamines for systemic use. Piperazine derivatives. ATX code R06A E07.

Pharmacological properties

Cetirizine, a metabolite of hydroxyzine in humans, is a potent selective antagonist of peripheral H1 receptors. In vitro receptor binding studies showed no affinity for receptors other than H1 receptors. In addition to antagonistic effects on H1-receptors, cetirizine has an antiallergic effect: at a dose of 10 mg 1 or 2 times a day, the drug inhibits the late phase of involvement of inflammatory cells, especially eosinophils, in the skin and conjunctiva of antigen-administered individuals. at a dose of 30 mg / day inhibits the influx of eosinophils in the bronchoalveolar fluid during the late phase of bronchoconstriction caused by inhalation of allergens in patients with asthma. In addition, cetirizine inhibits the late phase of the inflammatory response induced in patients with chronic urticaria by intradermal administration of kallikrein. It also reduces the adhesion of molecules such as ICAM-1 and VCAM-1, which are markers of allergic inflammation.

Indication

Zodak oral drops is indicated for the relief of nasal and ocular symptoms of seasonal and persistent allergic rhinitis and chronic idiopathic urticaria in adults and children 2 years of age and older.

Contraindication:

• hypersensitivity to cetirizine, to any component of the drug, to hydroxyzine or any piperazine derivatives in the history;
• severe renal impairment with creatinine clearance less than 10 ml / min.

Method of application and dosage

This drug Zodak oral drops should be used orally.

• Children aged 2 to 6 years: 2.5 mg 2 times a day (5 drops 2 times a day).
• Children aged 6 to 12 years: 5 mg 2 times a day (10 drops 2 times a day).
• Adults and children over 12 years: 10 mg 1 time per day (20 drops).

Children

The drug should be prescribed to children over 2 years of age.

Overdose:

• Symptoms. Symptoms seen after a significant overdose of cetirizine are mainly related to central nervous system effects or effects that may indicate anticholinergic effects. Side effects reported after taking at least 5 times the recommended daily dose include: confusion, diarrhea, vertigo, fatigue, headache, malaise, mydriasis, itching, restlessness, sedation, drowsiness, stupor, stupor, and , tremor, delayed urination.
• Treatment. The specific antidote for cetirizine is unknown. In case of overdose, symptomatic and supportive therapy is recommended. Gastric lavage should be performed as soon as possible after taking the drug. Cetirizine is ineffectively excreted during dialysis.

Side effects

Clinical studies have shown that cetirizine, when used at the recommended doses, has minor side effects on the central nervous system, including drowsiness, fatigue, vertigo, and headache. In some cases, paradoxical stimulation of the central nervous system has been reported.

Methyl parahydroxybenzoate and propyl parahydroxybenzoate, which are part of oral drops, can cause allergic reactions (possibly delayed).

Although cetirizine is a selective antagonist of peripheral H1 receptors and has almost no anticholinergic effects, there have been isolated reports of urinary incontinence, eye accommodation disorders, and dry mouth.